Filing Details
- Accession Number:
- 0001725160-23-000201
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-11-13 17:24:19
- Reporting Period:
- 2023-11-10
- Accepted Time:
- 2023-11-13 17:24:19
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 823607803 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1808098 | Michael David Johnson | C/O Zentalis Pharmaceuticals, Inc. 1359 Broadway, Suite 801 New York NY 10018 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-11-10 | 17,000 | $9.88 | 144,389 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct |
Footnotes
- The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.70 to $9.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Billionaire Hedge Funds
